---
title: "Hearing Loss"
order: 1
category: "Otolaryngology"
---

# Hearing Loss

## Overview

Hearing loss is one of the most common sensory deficits, affecting approximately 466 million people worldwide (6.1% of the global population). It ranges from mild difficulty understanding speech in noisy environments to profound deafness. Hearing loss significantly impacts communication, social interaction, cognitive function, and quality of life. Understanding the anatomy of the auditory system, classification of hearing loss, diagnostic evaluation, and treatment options is essential for all clinicians. Early identification and intervention can dramatically improve outcomes, particularly in children where hearing is critical for speech and language development.

### Epidemiology
- **Prevalence**: Increases with age - 25% of adults 65-74, 50% over 75
- **Congenital**: 1-3 per 1000 live births
- **Noise-induced**: Second most common cause after presbycusis
- **Impact**: Associated with social isolation, depression, cognitive decline, falls
- **Economic burden**: Significant healthcare and societal costs
- **Preventable**: Many causes preventable with hearing protection, vaccination

### Classification
- **By mechanism**: Conductive, sensorineural, mixed
- **By severity**: Mild, moderate, severe, profound
- **By onset**: Congenital, acquired
- **By progression**: Sudden, progressive, fluctuating
- **By laterality**: Unilateral, bilateral, asymmetric

## Auditory Anatomy and Physiology

### External Ear

#### Auricle (Pinna)
- **Function**: Sound collection and localization
- **Structure**: Elastic cartilage covered by skin
- **Landmarks**: Helix, antihelix, tragus, antitragus, lobule

#### External Auditory Canal
- **Length**: 2.5 cm in adults
- **Cartilaginous portion**: Outer 1/3, mobile
- **Bony portion**: Inner 2/3, fixed
- **Function**: Transmit sound to tympanic membrane, protection
- **Self-cleaning**: Epithelial migration carries cerumen outward

### Middle Ear

#### Tympanic Membrane
- **Layers**: Outer skin, middle fibrous, inner mucosa
- **Landmarks**: Umbo, handle of malleus, pars tensa, pars flaccida
- **Function**: Converts sound waves to mechanical vibration

#### Ossicular Chain
- **Three bones**: Malleus, incus, stapes
- **Function**: Amplification and impedance matching (air to fluid)
- **Gain**: 20-30 dB amplification
- **Lever action**: Malleus-incus lever arm
- **Area ratio**: Large TM to small oval window (17:1)

#### Middle Ear Space
- **Eustachian tube**: Connects to nasopharynx, equalizes pressure
- **Mastoid air cells**: Air-filled spaces in temporal bone
- **Muscles**: Stapedius (dampens loud sounds), tensor tympani

### Inner Ear (Cochlea)

#### Structure
- **Bony labyrinth**: Spiral canal in temporal bone (2.5 turns)
- **Membranous labyrinth**: Cochlear duct within bony labyrinth
- **Three compartments**:
  - Scala vestibuli (perilymph, connects to oval window)
  - Scala media (endolymph, contains organ of Corti)
  - Scala tympani (perilymph, connects to round window)

#### Organ of Corti
- **Location**: Basilar membrane within scala media
- **Hair cells**:
  - Inner hair cells: 3,500, primary sensory cells (95% of afferents)
  - Outer hair cells: 12,000, cochlear amplification, motility
- **Tectorial membrane**: Overlying structure
- **Function**: Converts mechanical vibration to neural signal

#### Tonotopic Organization
- **Base**: High frequencies (20,000 Hz), narrow, stiff basilar membrane
- **Apex**: Low frequencies (20 Hz), wide, flexible basilar membrane
- **Cochlear amplifier**: Outer hair cell motility enhances sensitivity and frequency selectivity

### Auditory Nerve (CN VIII)

#### Cochlear Division
- **Bipolar neurons**: Cell bodies in spiral ganglion
- **Fibers**: ~30,000 nerve fibers
- **Tonotopic organization**: Maintained throughout auditory pathway
- **Course**: Internal auditory canal → cerebellopontine angle → brainstem

#### Central Auditory Pathway
- **Cochlear nucleus**: First synapse in brainstem
- **Superior olivary complex**: Binaural processing
- **Inferior colliculus**: Midbrain integration
- **Medial geniculate**: Thalamic relay
- **Primary auditory cortex**: Temporal lobe (Heschl's gyrus)

## Classification of Hearing Loss

### Conductive Hearing Loss

#### Definition
Impaired sound transmission through the external or middle ear to the cochlea.

#### Characteristics
- **Pure tone audiometry**: Air-bone gap (air conduction worse than bone conduction)
- **Maximum loss**: ~60 dB (limit of middle ear contribution)
- **Weber test**: Lateralizes to affected ear
- **Rinne test**: Bone conduction > air conduction (negative Rinne)

#### Causes

**External ear:**
- Cerumen impaction (most common)
- Foreign body
- External otitis
- Atresia/stenosis of canal
- Exostoses, osteomas

**Tympanic membrane:**
- Perforation (traumatic, chronic infection)
- Tympanosclerosis (scarring)
- Myringitis

**Middle ear:**
- Otitis media (acute, chronic, effusion)
- Cholesteatoma
- Otosclerosis
- Ossicular discontinuity (trauma, erosion)
- Middle ear tumor (glomus, schwannoma)

### Sensorineural Hearing Loss (SNHL)

#### Definition
Damage to the cochlea (sensory) or auditory nerve/central pathways (neural).

#### Characteristics
- **Pure tone audiometry**: No air-bone gap (both air and bone conduction reduced equally)
- **Weber test**: Lateralizes to better ear
- **Rinne test**: Air conduction > bone conduction (positive Rinne, but both reduced)
- **Speech discrimination**: Often disproportionately affected

#### Causes

**Cochlear (sensory):**
- Presbycusis (age-related, most common)
- Noise-induced hearing loss
- Ototoxicity (aminoglycosides, cisplatin, loop diuretics)
- Ménière's disease
- Genetic/hereditary
- Infections (meningitis, measles, mumps)
- Autoimmune inner ear disease
- Labyrinthitis

**Retrocochlear (neural):**
- Vestibular schwannoma (acoustic neuroma)
- Cerebellopontine angle tumors
- Auditory neuropathy spectrum disorder
- Multiple sclerosis
- Stroke affecting auditory pathway

### Mixed Hearing Loss
- **Definition**: Combination of conductive and sensorineural components
- **Example**: Chronic otitis media with tympanic membrane perforation in elderly patient with presbycusis
- **Audiometry**: Air-bone gap present, but bone conduction also reduced beyond normal

## Clinical Evaluation

### History

#### Onset and Progression
- **Sudden**: Viral, vascular, autoimmune
- **Progressive**: Presbycusis, noise exposure, tumor
- **Fluctuating**: Ménière's disease, Eustachian tube dysfunction
- **Congenital vs acquired**: Age at onset

#### Laterality
- **Unilateral**: Tumor, sudden SNHL, Ménière's, trauma
- **Bilateral symmetric**: Presbycusis, noise-induced, genetic
- **Bilateral asymmetric**: Warrants investigation for retrocochlear pathology

#### Associated Symptoms
- **Tinnitus**: Ringing, buzzing (most SNHL causes)
- **Vertigo**: Ménière's, labyrinthitis, vestibular schwannoma
- **Otalgia**: Infection, tumor
- **Otorrhea**: Chronic otitis media, cholesteatoma
- **Aural fullness**: Eustachian tube dysfunction, Ménière's, effusion
- **Facial weakness**: Temporal bone fracture, cholesteatoma, tumor

#### Exposures and Risk Factors
- **Noise exposure**: Occupational, recreational (firearms, music)
- **Ototoxic medications**: Aminoglycosides, chemotherapy, loop diuretics
- **Head trauma**: Temporal bone fracture, labyrinthine concussion
- **Infections**: Meningitis, chronic ear infections
- **Family history**: Genetic hearing loss, otosclerosis

### Physical Examination

#### Otoscopic Examination
- **External canal**: Cerumen, foreign body, infection, stenosis
- **Tympanic membrane**:
  - Color: Normal pearly gray, erythema (infection), blue (hemotympanum)
  - Position: Neutral, retracted, bulging
  - Mobility: Pneumatic otoscopy (effusion reduces mobility)
  - Integrity: Perforation, scarring, retraction pocket
  - Landmarks: Malleus handle, light reflex, umbo

#### Tuning Fork Tests (512 Hz fork)

**Weber test:**
- **Technique**: Fork on forehead/vertex, ask where sound heard
- **Normal**: Midline or equal bilaterally
- **Conductive loss**: Lateralizes to affected ear
- **Sensorineural loss**: Lateralizes to better ear

**Rinne test:**
- **Technique**: Compare air conduction (fork near ear) to bone conduction (fork on mastoid)
- **Normal**: Air conduction > bone conduction (positive Rinne)
- **Conductive loss**: Bone conduction > air conduction (negative Rinne)
- **Sensorineural loss**: Air > bone (positive Rinne), but both reduced

**Schwabach test:**
- **Less commonly used**: Compare patient's bone conduction to examiner's

#### Cranial Nerve Examination
- **CN VII (facial)**: Facial movement, taste
- **CN VIII (vestibulocochlear)**: Hearing, balance
- **Other CNs**: If suspecting CPA tumor or central pathology

#### Head and Neck Examination
- **Nasopharynx**: Mass obstructing Eustachian tube
- **Neck**: Lymphadenopathy
- **Parotid**: Tumor involvement of facial nerve

### Diagnostic Testing

#### Audiometry

**Pure tone audiometry (PTA):**
- **Gold standard**: Objective measure of hearing thresholds
- **Air conduction**: 250-8000 Hz, tests entire auditory system
- **Bone conduction**: Bypasses outer/middle ear, tests cochlea directly
- **Results**:
  - Normal: 0-25 dB HL
  - Mild: 26-40 dB
  - Moderate: 41-55 dB
  - Moderately severe: 56-70 dB
  - Severe: 71-90 dB
  - Profound: >90 dB
- **Air-bone gap**: Difference indicates conductive component

**Speech audiometry:**
- **Speech reception threshold (SRT)**: Softest level for 50% word recognition
- **Word recognition score (WRS)**: Percent correct at comfortable loudness
- **Poor WRS**: Suggests retrocochlear pathology or severe cochlear damage

**Tympanometry:**
- **Measures**: Middle ear pressure and compliance
- **Type A**: Normal (peak at 0 daPa)
- **Type B**: Flat (effusion, perforation)
- **Type C**: Negative pressure (Eustachian tube dysfunction)
- **Type Ad**: High compliance (ossicular discontinuity)
- **Type As**: Low compliance (otosclerosis, tympanosclerosis)

**Acoustic reflex:**
- **Tests**: Stapedius muscle reflex
- **Absent**: Conductive loss >25 dB, facial nerve paralysis, auditory neuropathy

**Otoacoustic emissions (OAE):**
- **Principle**: Outer hair cell function produces measurable sounds
- **Present**: Normal cochlear function (up to outer hair cells)
- **Absent**: Cochlear hearing loss >30-40 dB
- **Use**: Newborn hearing screening, differentiate cochlear from retrocochlear

**Auditory brainstem response (ABR):**
- **Measures**: Neural transmission through brainstem
- **Waves**: I (cochlear nerve), III (pons), V (midbrain)
- **Uses**:
  - Threshold estimation (infants, uncooperative patients)
  - Retrocochlear screening (vestibular schwannoma)
  - Intraoperative monitoring
- **Abnormal**: Prolonged wave V latency or I-V interpeak interval suggests retrocochlear

#### Imaging

**MRI with gadolinium:**
- **Indications**:
  - Asymmetric SNHL (rule out vestibular schwannoma)
  - Retrocochlear signs (poor speech discrimination, abnormal ABR)
  - Progressive unilateral hearing loss
- **Protocol**: Thin-cut T1 with gadolinium, T2 sequences
- **Findings**: Vestibular schwannoma, other CPA tumors, labyrinthitis ossificans

**CT temporal bone:**
- **Indications**:
  - Conductive hearing loss (evaluate ossicles, middle ear)
  - Temporal bone fracture
  - Cholesteatoma
  - Congenital malformations
  - Pre-surgical planning
- **Protocol**: High-resolution, thin-cut (0.5-1 mm)
- **Findings**: Ossicular erosion, cholesteatoma, fracture, otosclerosis (in some cases)

## Specific Causes of Hearing Loss

### Presbycusis (Age-Related Hearing Loss)

#### Pathophysiology
- **Multifactorial**: Genetic predisposition, cumulative noise exposure, ototoxicity, vascular changes
- **Histopathology**:
  - Loss of hair cells (base to apex progression)
  - Loss of spiral ganglion neurons
  - Strial atrophy (reduced endocochlear potential)
  - Basilar membrane stiffening

#### Clinical Presentation
- **Bilateral symmetric SNHL**: Gradual progression
- **High-frequency loss**: Difficulty with consonants (s, f, th)
- **Speech discrimination**: "I can hear but can't understand"
- **Worse in noise**: Background noise interferes significantly
- **Tinnitus**: High-pitched ringing common

#### Diagnosis
- **PTA**: Bilateral symmetric downsloping audiogram
- **MRI**: Not required unless asymmetric

#### Treatment
- **Hearing aids**: First-line, most benefit if early
- **Assistive listening devices**: Amplified phones, TV systems
- **Cochlear implants**: Severe to profound bilateral loss
- **Audiologic rehabilitation**: Speechreading, communication strategies

### Noise-Induced Hearing Loss (NIHL)

#### Pathophysiology
- **Acoustic trauma**: Mechanical damage to hair cells and supporting structures
- **Metabolic exhaustion**: Excess stimulation depletes cellular energy
- **Excitotoxicity**: Glutamate overload
- **Free radical damage**: Oxidative stress
- **Permanent threshold shift**: Hair cell death

#### Risk Factors
- **Occupational**: Construction, military, manufacturing, agriculture
- **Recreational**: Firearms, music concerts, personal audio devices
- **Duration and intensity**: NIHA standard - 85 dB for 8 hours
- **Impulse noise**: Explosions, gunfire (higher risk)

#### Clinical Presentation
- **4000 Hz notch**: Classic audiogram finding
- **Bilateral symmetric**: Usually, unless asymmetric exposure
- **Tinnitus**: Very common, often high-pitched
- **Recruitment**: Abnormal growth of loudness perception
- **Initially reversible**: Temporary threshold shift (TTS) with rest

#### Prevention
- **Hearing protection**: Earplugs (20-30 dB reduction), earmuffs (20-40 dB)
- **Administrative controls**: Limit exposure time, rotate workers
- **Engineering controls**: Reduce noise at source, barriers
- **Education**: Awareness of risk
- **Hearing conservation programs**: OSHA-mandated for >85 dB TWA

#### Treatment
- **No cure**: Damage is permanent
- **Hearing aids**: If significant functional impairment
- **Prevent further loss**: Consistent hearing protection

### Sudden Sensorineural Hearing Loss (SSNHL)

#### Definition
≥30 dB hearing loss over at least 3 contiguous frequencies occurring within 72 hours.

#### Etiology
- **Idiopathic**: 85-90% of cases
- **Viral**: HSV, CMV, VZV (Ramsay Hunt syndrome), mumps
- **Vascular**: Hemorrhage, thrombosis, vasospasm
- **Autoimmune**: Autoimmune inner ear disease
- **Neoplastic**: Vestibular schwannoma (rare presentation)
- **Traumatic**: Perilymphatic fistula, temporal bone fracture
- **Ototoxicity**: Medication exposure

#### Clinical Presentation
- **Sudden onset**: Waking with hearing loss, during activity
- **Unilateral**: 95% of cases
- **Tinnitus**: Very common (70-80%)
- **Aural fullness**: Sensation of ear "plugged"
- **Vertigo**: 30-50% have associated vertigo

#### Diagnosis
- **PTA**: Confirm ≥30 dB loss over 3 contiguous frequencies
- **MRI with gadolinium**: Rule out vestibular schwannoma (obtain in all cases)
- **Laboratory**: Consider based on history (autoimmune panel, syphilis, Lyme if endemic)

#### Treatment (Time-Sensitive)
- **Oral corticosteroids**: Prednisone 1 mg/kg (max 60 mg) for 10-14 days, taper
  - **Evidence**: Modest benefit, AAO-HNS strongly recommends
  - **Start**: Within 14 days, ideally within 72 hours
- **Intratympanic steroids**: Dexamethasone or methylprednisolone injected through TM
  - **Indications**: Failed oral steroids, contraindication to systemic steroids
  - **Efficacy**: Similar or superior to oral in some studies
- **Hyperbaric oxygen**: Consider within 14 days if available (controversial, limited evidence)
- **Antivirals**: No proven benefit, not recommended

#### Prognosis
- **Spontaneous recovery**: 45-65% have some improvement without treatment
- **Complete recovery**: 35-39%
- **Prognostic factors**:
  - Better: Mild to moderate loss, low-frequency loss, early treatment, younger age, no vertigo
  - Worse: Severe to profound loss, presence of vertigo, delayed treatment

### Ménière's Disease

#### Definition
Inner ear disorder characterized by episodic vertigo, fluctuating hearing loss, tinnitus, and aural fullness.

#### Pathophysiology
- **Endolymphatic hydrops**: Distension of endolymphatic system
- **Mechanism**: Unclear (impaired absorption, overproduction, membrane rupture theory)
- **Result**: Episodic dysfunction

#### Diagnostic Criteria (AAO-HNS)
**Definite Ménière's disease:**
- ≥2 spontaneous episodes of vertigo, 20 minutes to 12 hours
- Audiometrically documented low-to-medium frequency SNHL in affected ear
- Fluctuating aural symptoms (hearing, tinnitus, fullness) in affected ear
- Not better explained by another diagnosis

#### Clinical Presentation
- **Vertigo attacks**: Severe, rotational, 20 minutes to several hours
- **Hearing loss**: Low-frequency SNHL initially, fluctuating
- **Tinnitus**: Roaring, low-pitched, fluctuates with attacks
- **Aural fullness**: Pressure sensation
- **Progression**: Eventually permanent SNHL, less frequent vertigo attacks

#### Diagnosis
- **Clinical**: Based on criteria above
- **PTA**: Low-frequency SNHL, fluctuating
- **MRI**: Rule out vestibular schwannoma, labyrinthitis

#### Treatment

**Acute attack:**
- Vestibular suppressants: Meclizine, diazepam
- Antiemetics: Promethazine, ondansetron
- Rest

**Prophylaxis:**
- **Low-sodium diet**: <1500-2000 mg/day
- **Diuretics**: Hydrochlorothiazide/triamterene (limited evidence)
- **Betahistine**: Used in Europe, not FDA-approved in US
- **Lifestyle**: Avoid triggers (caffeine, alcohol, stress)

**Refractory cases:**
- **Intratympanic gentamicin**: Chemical ablation of vestibular function (preserves hearing in many)
- **Intratympanic steroids**: Alternative to gentamicin
- **Endolymphatic sac decompression**: Surgery to reduce pressure (controversial efficacy)
- **Vestibular nerve section**: Definitive for vertigo, preserves hearing
- **Labyrinthectomy**: Eliminates vertigo, sacrifices hearing (for non-functional ear)

### Otosclerosis

#### Pathophysiology
- **Abnormal bone remodeling**: Spongiotic bone replaces normal otic capsule
- **Stapes fixation**: Abnormal bone at oval window fixes stapes footplate
- **Conductive hearing loss**: Impaired ossicular chain movement
- **Cochlear otosclerosis**: If extends to cochlea, SNHL component (10-15%)

#### Epidemiology
- **Prevalence**: 0.3-0.4% of Caucasians, rare in other ethnicities
- **Age**: Onset 20s-40s, progresses during pregnancy
- **Gender**: Female predominance (2:1)
- **Genetics**: Autosomal dominant with incomplete penetrance, multifactorial

#### Clinical Presentation
- **Progressive conductive hearing loss**: Bilateral (80%), asymmetric
- **Carhart notch**: Bone conduction dip at 2000 Hz (artifact, not true SNHL)
- **Tinnitus**: Common
- **Paracusis Willisi**: Hear better in noisy environment (paradoxical)
- **Normal otoscopy**: TM appears normal
- **Schwartze sign**: Reddish hue behind TM from hypervascularity (rare)

#### Diagnosis
- **PTA**: Conductive hearing loss, air-bone gap
- **Tympanometry**: Type As (low compliance, fixed stapes)
- **CT temporal bone**: May show lucency at fissula ante fenestram, thickened stapes (not required for diagnosis)

#### Treatment

**Observation:**
- Mild hearing loss, no functional impairment

**Hearing aids:**
- Effective for conductive component
- Non-surgical option

**Stapedectomy/stapedotomy:**
- **Procedure**: Remove stapes, replace with prosthesis
- **Success rate**: 90-95% close air-bone gap to <10 dB
- **Complications**:
  - Sensorineural hearing loss: 1-2%
  - Vertigo: Temporary in many, persistent rare
  - Dysgeusia: Altered taste (chorda tympani nerve)
  - Tinnitus: May improve, worsen, or develop
  - Total hearing loss: <1%
- **Timing**: One ear at a time (at least 6-12 months apart)

**Fluoride therapy:**
- **Controversial**: May slow cochlear otosclerosis
- **Not FDA-approved**: For this indication

### Vestibular Schwannoma (Acoustic Neuroma)

#### Pathophysiology
- **Benign tumor**: Schwann cells of vestibular portion of CN VIII
- **Location**: Cerebellopontine angle, internal auditory canal
- **Growth**: Slow-growing (1-2 mm/year average), variable

#### Epidemiology
- **Incidence**: 1 per 100,000 per year
- **Age**: Peak 40-60 years
- **Bilateral**: Neurofibromatosis type 2 (NF2)

#### Clinical Presentation
- **Asymmetric SNHL**: Most common presenting symptom (95%)
- **Tinnitus**: Unilateral, high-pitched (70%)
- **Imbalance**: More than acute vertigo (disequilibrium)
- **Large tumors**: Facial numbness (CN V), facial weakness (CN VII), hydrocephalus

#### Diagnosis
- **MRI with gadolinium**: Diagnostic, tumor enhances
- **Size**: Measured in largest diameter
- **ABR**: Abnormal in 90% (prolonged I-V interpeak latency), used historically

#### Treatment

**Observation:**
- **Indications**: Small tumor, elderly, poor surgical candidate, only hearing ear
- **Monitoring**: Serial MRI (annually initially, then q2-3 years if stable)
- **Growth**: 30-50% show no growth

**Microsurgery:**
- **Approaches**:
  - Translabyrinthine: Sacrifices hearing, good facial nerve preservation, any size
  - Middle cranial fossa: Preserves hearing (if serviceable), small tumors in IAC
  - Retrosigmoid: Hearing preservation attempt, any size
- **Goal**: Tumor removal, preserve facial nerve function
- **Hearing preservation**: Possible in 50-70% of small tumors with serviceable hearing
- **Complications**: Facial weakness, CSF leak, headache, hearing loss

**Stereotactic radiosurgery:**
- **Technique**: Gamma Knife, CyberKnife, linear accelerator
- **Dose**: 12-13 Gy to tumor margin (single fraction)
- **Tumor control**: 90-95% at 5-10 years (stop growth)
- **Hearing preservation**: 50-70% maintain serviceable hearing
- **Indications**: Small to medium tumors (<3 cm), poor surgical candidate, patient preference
- **Complications**: Facial/trigeminal neuropathy (rare), malignant transformation (very rare)

## Hearing Rehabilitation

### Hearing Aids

#### Types
- **Behind-the-ear (BTE)**: Most powerful, durable, easiest to handle
- **In-the-ear (ITE)**: Custom-molded, fills concha
- **In-the-canal (ITC)**: Smaller, less visible
- **Completely-in-canal (CIC)**: Invisible, least powerful
- **Receiver-in-canal (RIC)**: Speaker in ear canal, popular

#### Technology
- **Digital signal processing**: Noise reduction, directional microphones, feedback cancellation
- **Wireless connectivity**: Bluetooth, smartphone apps
- **Rechargeable batteries**: Lithium-ion

#### Candidacy
- **Mild to severe hearing loss**: Most benefit
- **Symmetric bilateral loss**: Binaural amplification ideal
- **Motivation**: Success depends on regular use

#### Limitations
- **Cannot restore normal hearing**: Amplification only
- **Occlusion effect**: Own voice sounds hollow
- **Maintenance**: Cleaning, battery replacement
- **Cost**: $1,000-$6,000 per device, often not covered by insurance

### Cochlear Implants

#### Mechanism
- **Bypass damaged hair cells**: Directly stimulate auditory nerve
- **Components**:
  - External: Microphone, speech processor, transmitter
  - Internal: Receiver/stimulator, electrode array (inserted in cochlea)

#### Candidacy (FDA Criteria)
- **Adults**: Severe to profound bilateral SNHL, poor speech discrimination (<50%) with hearing aids
- **Children**: Profound bilateral SNHL (12-24 months), severe to profound (2-17 years)
- **Anatomy**: Patent cochlea, functioning auditory nerve
- **Motivation**: Commitment to rehabilitation

#### Outcomes
- **Speech understanding**: Highly variable (0-100% open-set sentence recognition)
- **Factors**: Duration of deafness, age at implantation, cognitive factors
- **Children**: Best outcomes if implanted before age 3
- **Adults**: Best if short duration of deafness

#### Complications
- **Surgical**: Facial nerve injury (rare), device failure, infection, hematoma
- **Medical**: Meningitis (vaccination recommended), vertigo
- **Device**: Failure rate 2-5% (require reimplantation)

### Assistive Listening Devices
- **FM systems**: Teacher wears microphone, student receives via hearing aid or headphones
- **Loop systems**: Electromagnetic signal to telecoil-equipped hearing aids
- **Captioning**: Real-time captions for TV, meetings
- **Amplified phones**: For telephone use
- **Alerting devices**: Visual or vibrating alerts for doorbells, alarms

## Pediatric Considerations

### Newborn Hearing Screening
- **Universal screening**: Recommended in all states
- **Timing**: Before hospital discharge
- **Method**: OAE or ABR
- **Refer if fail**: Comprehensive audiologic evaluation by 3 months
- **Early intervention**: Start by 6 months for best language outcomes

### Congenital Hearing Loss

#### Causes
- **Genetic**: 50-60% of congenital hearing loss
  - Syndromic (30%): Usher, Waardenburg, Pendred, Jervell and Lange-Nielsen, others
  - Non-syndromic (70%): GJB2 (connexin 26) most common
- **Acquired**:
  - Congenital infections: CMV (most common), rubella, toxoplasmosis, syphilis
  - Prematurity: <1500 g, NICU stay >5 days
  - Hyperbilirubinemia: Kernicterus
  - Ototoxic medications: Aminoglycosides in neonatal period

#### Evaluation
- **Audiometry**: ABR, behavioral audiometry
- **Imaging**: MRI/CT for inner ear malformations
- **Genetic testing**: GJB2, comprehensive panels
- **CMV testing**: Urine or saliva PCR (if <3 weeks)
- **Ophthalmology**: Syndromic associations
- **Cardiology**: Jervell and Lange-Nielsen (long QT)

#### Management
- **Hearing aids**: Trial first
- **Cochlear implants**: If profound bilateral, FDA approved ≥12 months
- **Speech therapy**: Essential component
- **Educational support**: IEP, specialized services

### Developmental Milestones
- **Birth-3 months**: Startles to loud sounds
- **4-6 months**: Turns to voice
- **7-12 months**: Babbling, responds to name
- **12-18 months**: First words
- **18-24 months**: Two-word phrases
- **2-3 years**: Simple sentences

## Prevention and Public Health

### Noise Exposure
- **NIOSH/OSHA standards**: Hearing conservation programs
- **Personal protection**: Earplugs, earmuffs
- **Education**: Awareness of recreational noise risks

### Ototoxicity Prevention
- **Aminoglycosides**: Therapeutic drug monitoring, avoid if possible
- **Chemotherapy**: Counsel patients, consider otoprotective agents (under investigation)
- **Loop diuretics**: Use lowest effective dose

### Immunization
- **Measles, mumps, rubella**: Prevent infectious causes
- **Pneumococcal, Hib, meningococcal**: Reduce meningitis risk
- **Influenza**: Reduce complications

### Screening
- **Universal newborn**: Identify congenital loss
- **School-age**: Periodic screening
- **Adults**: Baseline at age 50, then periodically

## Summary

Hearing loss is a common and impactful condition affecting millions worldwide. It is classified by mechanism (conductive, sensorineural, mixed), severity (mild to profound), and onset (congenital, acquired). Comprehensive evaluation includes detailed history, physical examination with otoscopy and tuning fork tests, and audiometric testing. Imaging is indicated for asymmetric SNHL to rule out retrocochlear pathology. Common causes include presbycusis (age-related), noise-induced hearing loss, otosclerosis, sudden SNHL, Ménière's disease, and vestibular schwannoma. Treatment ranges from medical management and hearing aids to surgical interventions and cochlear implants. Early identification through newborn screening and prompt intervention are critical for optimal language development in children. Prevention through hearing protection, ototoxicity awareness, and vaccination can reduce the burden of hearing loss. Understanding the breadth of causes, diagnostic approaches, and treatment options enables clinicians to effectively manage patients with hearing loss and improve quality of life.
